Deborah Lindquist

5.5k citations
26 papers · 3.2k · 1 hit paper · h-index 11

Impact in

  • Oncology top 1%
    • HER2/EGFR in Cancer Research
    • Cancer Treatment and Pharmacology
    • Colorectal Cancer Treatments and Studies
    • Peptidase Inhibition and Analysis
  • Cancer Research top 5%
    • Breast Cancer Treatment Studies

Papers in

  • Oncology 15
    • HER2/EGFR in Cancer Research 10
    • Cancer Treatment and Pharmacology 8
    • Lung Cancer Research Studies 2
  • Pulmonary and Respiratory Medicine 9
    • Advanced Breast Cancer Therapies 6
    • Lung Cancer Treatments and Mutations 3
Co-authors
David Cameron (3 shared papers)Agnieszka Jagiełło-Gruszfeld (1 shared paper)Mario Campone (1 shared paper)Neville Davidson (1 shared paper)Dimosthenis Skarlos (1 shared paper)Mark S. Berger (1 shared paper)Tadeusz Pieńkowski (1 shared paper)Arlene Chan (1 shared paper)
Journals
Journal of Clinical Oncology (8 papers)Cancer Research (3 papers)The Lancet Oncology (2 papers)European Journal of Cancer (2 papers)Breast Cancer Research and Treatment (2 papers)
Partner nations
United StatesUnited KingdomFrance

In The Last Decade

Deborah Lindquist

25 papers receiving 3.1k citations

Deborah Lindquist's Hit Papers

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer 2006 · 2.6k citations
2.6k0+6+13Years since publication50010001.5k2.0k2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2006 New England Journal of Medicine

Peers

Deborah Lindquist
Comparison fields: 5 of 83
  • Oncology 2.3k
  • Cancer Research 565
  • Radiology, Nuclear Medicine and Imaging 634
  • Pulmonary and Respiratory Medicine 787
  • Genetics 226
Replace Steven Stein with:
Steven Stein United States
Zefei Jiang China
Michael W. Lu United States
Stephen D. Rubin United States
Binghe Xu China
Alexey Manikhas Russia
José Luiz Pedrini Brazil
Giancarlo Bisagni Italy
Filippo Montemurro Italy
Nancy T. Sklarin United States
Deborah Lindquist relative to Steven Stein United States Steven Stein's profile →
Citations per field
00.5×1.5×
Steven Stein · 1×
Citations per year

Countries citing papers authored by Deborah Lindquist

Since Specialization
Citations

This map shows the geographic impact of Deborah Lindquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Lindquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Lindquist more than expected).

Fields of papers citing papers by Deborah Lindquist

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Lindquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Lindquist. The network helps show where Deborah Lindquist may publish in the future.

Co-authors

The 25 scholars most cited alongside Deborah Lindquist, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deborah Lindquist Line = papers co-authored together Deborah Lindquist links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
New England Journal of Medicine ·Charles E. Geyer, John Forster, Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pieńkowski, Agnieszka Jagiełło-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark S. Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron
Hit paper breakdown →		20062638
2
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
The Lancet Oncology ·Paul E. Goss, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Manfred Kaufmann, Frances Boyle, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Yanin Chávarri-Guerra, Gursel Aktan, Erica Rappold, Lisa S. Williams, Dianne M. Finkelstein
2012106
3
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
The Lancet Oncology ·Stephen E. Jones, Rufus Collea, Devchand Paul, Scot Sedlacek, Anne Favret, Ira Gore, Deborah Lindquist, Frankie A. Holmes, Mary Ann Allison, Barry Don Brooks, Raul M Portillo, Svetislava J. Vukelja, Michael S. Steinberg, Christopher Stokoe, M Crockett, Yunfei Wang, Lina Asmar, Nicholas J. Robert, Joyce O’Shaughnessy
201396
4
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
Breast Cancer Research and Treatment ·Joyce O’Shaughnessy, Katarína Petráková, Gabe S. Sonke, PierFranco Conte, Carlos L. Arteaga, David Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, J. Thaddeus Beck, Deborah Lindquist, Farida Souami, S. Mondal, Caroline Germa, Gabriel N. Hortobágyi
201788
5
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
Breast Cancer Research and Treatment ·Linda T. Vahdat, Agustin A. García, Charles L. Vogel, Christine Pellegrino, Deborah Lindquist, Nicholas Iannotti, Prashanth Gopalakrishna, Joseph A. Sparano
201350
6
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Clinical Cancer Research ·Joyce O’Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen, Lea Krekow, Frankie A. Holmes, Svetislava J. Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert J. Brooks, Kristi McIntyre, Carrie Brownstein, Silke Hoersch, Joanne L. Blum, Stephen E. Jones
201538
7
Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
Cancer Research ·Joyce O’Shaughnessy, D Paul, Christopher Stokoe, John Pippen, JL Blum, Lea Krekow, FA Holmes, Svetislava J. Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert J. Brooks, Kristi McIntyre, Robert Pluenneke, Jonathan Schwartz, Sharon Jones, Carrie Brownstein, Frank Gilberg
201029
8
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Breast Cancer Research ·Kathrin Strasser‐Weippl, Nora Horick, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Frances Boyle, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Erica Rappold, Dianne M. Finkelstein, Paul E. Goss
201526
9
Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer
Journal of Clinical Oncology ·David Loesch, F. Anthony Greco, Neil Senzer, Howard A. Burris, John D. Hainsworth, Stephen E. Jones, Svetislava J. Vukelja, John F. Sandbach, Frankie A. Holmes, Scot Sedlacek, John Pippen, Deborah Lindquist, Kristi McIntyre, Joanne L. Blum, Manuel Modiano, Kristi A. Boehm, Feng Zhan, Lina Asmar, Nicholas J. Robert
201018
10
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
Lung Cancer ·Marcus A. Neubauer, David Garfield, Paul R. Kuerfler, Robert N. Raju, Deborah Lindquist, Edward S. Soo, Myrna M. Khan, Kristi A. Boehm, Lina Asmar
200416
11
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
npj Breast Cancer ·Devchand Paul, Svetislava J. Vukelja, Frankie A. Holmes, Joanne L. Blum, Kristi McIntyre, Deborah Lindquist, Cynthia R. Osborne, Ines J. Sanchez, Jerome H. Goldschmidt, Yunfei Wang, Lina Asmar, Lewis C. Strauss, Joyce O’Shaughnessy
201912
12
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer
European Journal of Cancer ·Frances Boyle, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Mayur M. Amonkar, Yingjie Huang, Erica Rappold, Lisa S. Williams, Jing Wang-Silvanto, Tomomi Kaneko, Dianne M. Finkelstein, Paul E. Goss
20159
13
Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.
Journal of Clinical Oncology ·John Pippen, Devchand Paul, Christopher Stokoe, Joanne L. Blum, Lea Krekow, F. A. Holmes, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert J. Brooks, S. Vukelja, Kristi McIntyre, Christine Lopez‐Diaz, J. O’Shaughnessy
20119
14
Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study
Annals of Oncology ·Rufus Collea, Flavio Kruter, James E. Cantrell, Timothy George, Stefan Krüger, Anne Favret, Deborah Lindquist, A. Melnyk, Robert Pluenneke, Spencer H. Shao, M Crockett, Lina Asmar, J. O’Shaughnessy
20128
15
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non–Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib
Clinical Lung Cancer ·M Sakamoto, Justin M. Honce, Deborah Lindquist, D. Ross Camidge
20186
16
Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
Case Reports in Oncology ·Lauren Ogawa, Deborah Lindquist
20184
17
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
European Journal of Cancer ·Kathrin Strasser‐Weippl, Nora Horick, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Frances Boyle, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Erica Rappold, Dianne M. Finkelstein, Paul E. Goss
20164
18
Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.
Journal of Clinical Oncology ·Joyce O’Shaughnessy, John Pippen, Devchand Paul, Christopher Stokoe, Joanne L. Blum, Lea Krekow, Frankie A. Holmes, Christine Lopez‐Diaz, Svetislava J. Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert J. Brooks, Kristi McIntyre, Yunfei Wang
20123
19
Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2
Lung Cancer ·Charles H. Weissman, John F. Sandbach, R. J. Brooker, Mark Vellek, Deborah Lindquist, Paul Conkling, D. Ilegbodu, Lina Asmar
20062
20
Abstract P4-22-05: First-line ribociclib plus letrozole in patients with de novo HR+, HER2– advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial
Cancer Research ·Joyce O’Shaughnessy, Katarína Petráková, GS Sonke, Fabrice André, PierFranco Conte, CL Arteaga, David Cameron, L. Hart, Cristian Villanueva, EH Jakobsen, Deborah Lindquist, Farida Souami, Xue Li, Caroline Germa, Samit Hirawat, GN Hortobagyi
20172

About Deborah Lindquist

Deborah Lindquist is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Dermatology and Molecular Biology, having authored 26 papers that have together received 3.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (6 papers), Chemotherapy-related skin toxicity (3 papers), Lung Cancer Treatments and Mutations (3 papers), Lung Cancer Research Studies (2 papers) and Estrogen and related hormone effects (1 paper). The work is most often cited by research in Oncology (2.3k citations), Cancer Research (565 citations), Radiology, Nuclear Medicine and Imaging (634 citations), Pulmonary and Respiratory Medicine (787 citations) and Genetics (226 citations). Deborah Lindquist has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include David Cameron, Agnieszka Jagiełło-Gruszfeld, Mario Campone, Neville Davidson, Dimosthenis Skarlos, Mark S. Berger, Tadeusz Pieńkowski, Arlene Chan, Charles E. Geyer and Stephen D. Rubin. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, The Lancet Oncology, European Journal of Cancer and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven SteinBreakdown of academic impact, for papers by Zefei JiangBreakdown of academic impact, for papers by Michael W. LuBreakdown of academic impact, for papers by Stephen D. RubinBreakdown of academic impact, for papers by Binghe XuBreakdown of academic impact, for papers by Alexey ManikhasBreakdown of academic impact, for papers by José Luiz PedriniBreakdown of academic impact, for papers by Giancarlo BisagniBreakdown of academic impact, for papers by Filippo MontemurroBreakdown of academic impact, for papers by Nancy T. Sklarin